As part of the APAC Symposium 2021, the APAC Community selected 4 studies to push into 2022. We would love to have folks around the world join us and help us with these studies. I’ve created a poll for anyone who has an interest in joining the study groups for each study (https://forms.office.com/r/K77ijSreyR). If you have an interest, please fill out this poll. If you want to participate in more than 1 study, you will have to fill this out more than once.
Study 1: Characterization of non-communicable disease across the pre- and post- COVID-19 era (Korea)
- Aim: Identification of the incidence, prevalence, and treatment pattern of non-communicable diseases (especially hypertension and diabetes mellitus) across the pre- and post-COVID-19 era.
Study 2: Quality assessment of CDM databases across the OHDSI-AP network (Korea)
- Aim: The goal of the inspection report is to provide insight into the completeness, transparency, and quality of the performed ETL process and the readiness of the data partner to be onboarded in OHDSI-AP network and participate in research studies. We will ask institutions to execute CdmInspection Package (https://github.com/ABMI/CdmInspection)
Study 3: Real world safety of treatments for multiple sclerosis (Australia)
- Utilisation patterns and treatment pathways of treatments in MS
- Risk of serious infections and virus reactivation (e.g TB, HepB, herpes zoster) in people treated with biologic medicines
Study 4: Comparison of mortality, morbidities & healthcare resources utilisation between patients with and without a diagnosis of COVID-19; (China)